Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance.

Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB.

Cancers (Basel). 2019 Jul 1;11(7). pii: E923. doi: 10.3390/cancers11070923. Review.

2.

High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.

Bertelsen B, Tuxen IV, Yde CW, Gabrielaite M, Torp MH, Kinalis S, Oestrup O, Rohrberg K, Spangaard I, Santoni-Rugiu E, Wadt K, Mau-Sorensen M, Lassen U, Nielsen FC.

NPJ Genom Med. 2019 Jun 21;4:13. doi: 10.1038/s41525-019-0087-6. eCollection 2019.

3.

Application of cell-free DNA for genomic tumor profiling: a feasibility study.

Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O.

Oncotarget. 2019 Feb 15;10(14):1388-1398. doi: 10.18632/oncotarget.26642. eCollection 2019 Feb 15.

4.

Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.

Chapel DB, Churg A, Santoni-Rugiu E, Tsujimura T, Hiroshima K, Husain AN.

Lung Cancer. 2019 Jan;127:69-75. doi: 10.1016/j.lungcan.2018.11.032. Epub 2018 Nov 26. Review.

PMID:
30642555
5.

Immune regulation by fibroblasts in tissue injury depends on uPARAP-mediated uptake of collectins.

Jürgensen HJ, Nørregaard KS, Sibree MM, Santoni-Rugiu E, Madsen DH, Wassilew K, Krustrup D, Garred P, Bugge TH, Engelholm LH, Behrendt N.

J Cell Biol. 2019 Jan 7;218(1):333-349. doi: 10.1083/jcb.201802148. Epub 2018 Oct 26.

6.

Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.

Tuxen IV, Rohrberg KS, Oestrup O, Ahlborn LB, Schmidt AY, Spanggaard I, Hasselby JP, Santoni-Rugiu E, Yde CW, Mau-Sørensen M, Nielsen FC, Lassen U.

Clin Cancer Res. 2019 Feb 15;25(4):1239-1247. doi: 10.1158/1078-0432.CCR-18-1780. Epub 2018 Oct 1.

PMID:
30274980
7.

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors.

Ahlborn LB, Tuxen IV, Mouliere F, Kinalis S, Schmidt AY, Rohrberg KS, Santoni-Rugiu E, Nielsen FC, Lassen U, Yde CW, Oestrup O, Mau-Sorensen M.

Oncotarget. 2018 Aug 24;9(66):32570-32579. doi: 10.18632/oncotarget.25948. eCollection 2018 Aug 24.

8.

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.

Jakobsen JN, Santoni-Rugiu E, Grauslund M, Melchior L, Sørensen JB.

Oncotarget. 2018 May 25;9(40):26195-26208. doi: 10.18632/oncotarget.25490. eCollection 2018 May 25.

9.

Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim).

Gajewska ME, Sritharan SS, Santoni-Rugiu E, Bendstrup EM.

Respir Med Case Rep. 2018 Feb 23;23:167-169. doi: 10.1016/j.rmcr.2018.02.005. eCollection 2018.

10.

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.

Buhl IK, Santoni-Rugiu E, Ravn J, Hansen A, Christensen IJ, Jensen T, Pratt B, Askaa J, Jensen PB, Knudsen S, Sørensen JB.

PLoS One. 2018 Mar 22;13(3):e0194609. doi: 10.1371/journal.pone.0194609. eCollection 2018.

11.

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.

Santoni-Rugiu E, Grauslund M, Melchior LC, Costa JC, Sørensen JB, Urbanska EM.

Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1.

12.

CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.

Engelholm LH, Riaz A, Serra D, Dagnæs-Hansen F, Johansen JV, Santoni-Rugiu E, Hansen SH, Niola F, Frödin M.

Gastroenterology. 2017 Dec;153(6):1662-1673.e10. doi: 10.1053/j.gastro.2017.09.008. Epub 2017 Sep 18.

13.

High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.

Zimling ZG, Santoni-Rugiu E, Bech C, Sørensen JB.

Anticancer Res. 2015 Dec;35(12):6731-8.

PMID:
26637889
14.

Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.

Andersen M, Trapani D, Ravn J, Sørensen JB, Andersen CB, Grauslund M, Santoni-Rugiu E.

Anticancer Res. 2015 Nov;35(11):6223-9.

PMID:
26504055
15.

[Unexpected bronchoscopic findings in sarcoidosis].

Gottlieb M, Perch M, Santoni-Rugiu E, Arendrup MC, Bjarnason NH.

Ugeskr Laeger. 2015 Aug 17;177(34):1630. Danish. No abstract available.

PMID:
26320587
16.

Molecular imaging in Libman-Sacks endocarditis.

Dahl A, Schaadt BK, Santoni-Rugiu E, Bruun NE.

Infect Dis (Lond). 2015 Apr;47(4):263-6. doi: 10.3109/00365548.2014.984323. Epub 2015 Jan 23.

PMID:
25622944
17.

C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma.

Jacobsen B, Kriegbaum MC, Santoni-Rugiu E, Ploug M.

World J Clin Oncol. 2014 Oct 10;5(4):621-32. doi: 10.5306/wjco.v5.i4.621. Review.

18.

Personalized oncology: genomic screening in phase 1.

Tuxen IV, Jønson L, Santoni-Rugiu E, Hasselby JP, Nielsen FC, Lassen U.

APMIS. 2014 Aug;122(8):723-33. doi: 10.1111/apm.12293. Review.

PMID:
25046202
19.

Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer.

Vilmar A, Santoni-Rugiu E, Cillas JG, Huarriz M, Sørensen JB.

Anticancer Res. 2014 Jun;34(6):2991-6.

PMID:
24922664
20.

Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.

Andersen M, Grauslund M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E.

J Mol Diagn. 2014 Jul;16(4):418-30. doi: 10.1016/j.jmoldx.2014.03.002. Epub 2014 Jun 6.

PMID:
24912849
21.

Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.

Jakobsen JN, Santoni-Rugiu E, Sørensen JB.

J Cancer Res Clin Oncol. 2014 Apr;140(4):645-52. doi: 10.1007/s00432-014-1614-6. Epub 2014 Feb 23.

PMID:
24562672
22.

Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer.

Jakobsen JN, Santoni-Rugiu E, Sørensen JB.

Cancer Chemother Pharmacol. 2014 Jan;73(1):131-7. doi: 10.1007/s00280-013-2329-0. Epub 2013 Dec 11.

PMID:
24326616
23.
24.

Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer.

Jakobsen JN, Santoni-Rugiu E, Sørensen JB.

Histopathology. 2014 Feb;64(3):412-20. doi: 10.1111/his.12264. Epub 2013 Nov 25.

PMID:
24266856
25.

Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients.

Jakobsen JN, Santoni-Rugiu E, Sørensen JB.

Cancer Chemother Pharmacol. 2014 Jan;73(1):43-51. doi: 10.1007/s00280-013-2315-6. Epub 2013 Nov 13.

PMID:
24220933
26.

Loss of miR-10a activates lpo and collaborates with activated Wnt signaling in inducing intestinal neoplasia in female mice.

Stadthagen G, Tehler D, Høyland-Kroghsbo NM, Wen J, Krogh A, Jensen KT, Santoni-Rugiu E, Engelholm LH, Lund AH.

PLoS Genet. 2013 Oct;9(10):e1003913. doi: 10.1371/journal.pgen.1003913. Epub 2013 Oct 24.

27.

Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression.

Galli GG, Multhaupt HA, Carrara M, de Lichtenberg KH, Christensen IB, Linnemann D, Santoni-Rugiu E, Calogero RA, Lund AH.

Oncogene. 2014 Jun 19;33(25):3342-50. doi: 10.1038/onc.2013.283. Epub 2013 Jul 22.

28.

Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.

Jakobsen JN, Santoni-Rugiu E, Ravn J, Sørensen JB.

Eur J Cancer. 2013 Jul;49(11):2494-503. doi: 10.1016/j.ejca.2013.04.003. Epub 2013 Apr 29.

PMID:
23639410
29.

Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.

Jacobsen B, Muley T, Meister M, Dienemann H, Christensen IJ, Santoni-Rugiu E, Lærum OD, Ploug M.

J Thorac Oncol. 2013 Feb;8(2):152-60. doi: 10.1097/JTO.0b013e318279d503.

30.

[Lack of uniformity in the treatment of thymomas].

Abildgaard J, Pappot H, Petersen PM, Rørth M, Pedersen JH, Santoni-Rugiu E, Daugaard G.

Ugeskr Laeger. 2012 Dec 10;174(50):3164-9. Danish.

PMID:
23286768
31.

Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.

Vilmar AC, Santoni-Rugiu E, Sorensen JB.

Ann Oncol. 2013 Feb;24(2):309-14. doi: 10.1093/annonc/mds335. Epub 2012 Oct 4.

PMID:
23038758
32.

A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.

Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E.

Cancer Chemother Pharmacol. 2012 Nov;70(5):743-54. doi: 10.1007/s00280-012-1965-0. Epub 2012 Sep 8.

PMID:
22960937
33.

Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma?

Andersen M, Grauslund M, Muhammad-Ali M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E.

APMIS. 2012 Sep;120(9):767-9. doi: 10.1111/j.1600-0463.2012.02891.x. Epub 2012 Mar 5. No abstract available.

PMID:
22882267
34.

No effect of NGAL/lipocalin-2 on aggressiveness of cancer in the MMTV-PyMT/FVB/N mouse model for breast cancer.

Cramer EP, Glenthøj A, Häger M, Juncker-Jensen A, Engelholm LH, Santoni-Rugiu E, Lund LR, Laerum OD, Cowland JB, Borregaard N.

PLoS One. 2012;7(6):e39646. doi: 10.1371/journal.pone.0039646. Epub 2012 Jun 21.

35.

The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.

Zimling ZG, Jørgensen A, Santoni-Rugiu E.

Histopathology. 2012 May;60(6B):E96-105. doi: 10.1111/j.1365-2559.2012.04196.x. Epub 2012 Mar 6.

PMID:
22394205
36.

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, Andersson M, Ewertz M.

Ann Oncol. 2012 Aug;23(8):2034-42. doi: 10.1093/annonc/mdr546. Epub 2011 Dec 15.

PMID:
22172323
37.

Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.

Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E.

J Thorac Oncol. 2012 Jan;7(1):249-56. doi: 10.1097/JTO.0b013e318233d6a9.

38.

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.

Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E, Sorensen JB.

Lung Cancer. 2012 Mar;75(3):306-12. doi: 10.1016/j.lungcan.2011.08.016. Epub 2011 Oct 13.

PMID:
21996087
39.

Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma.

Alpízar-Alpízar W, Christensen IJ, Santoni-Rugiu E, Skarstein A, Ovrebo K, Illemann M, Laerum OD.

Int J Cancer. 2012 Aug 15;131(4):E329-36. doi: 10.1002/ijc.26417. Epub 2011 Oct 20.

40.

Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.

Jacobsen B, Santoni-Rugiu E, Illemann M, Kriegbaum MC, Laerum OD, Ploug M.

Int J Cancer. 2012 Jun 1;130(11):2734-9. doi: 10.1002/ijc.26305. Epub 2011 Aug 24.

41.

Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.

Vilmar AC, Santoni-Rugiu E, Sørensen JB.

Clin Cancer Res. 2011 Aug 1;17(15):5205-14. doi: 10.1158/1078-0432.CCR-11-0658. Epub 2011 Jun 20.

42.

MMSET is highly expressed and associated with aggressiveness in neuroblastoma.

Hudlebusch HR, Skotte J, Santoni-Rugiu E, Zimling ZG, Lees MJ, Simon R, Sauter G, Rota R, De Ioris MA, Quarto M, Johansen JV, Jørgensen M, Rechnitzer C, Maroun LL, Schrøder H, Petersen BL, Helin K.

Cancer Res. 2011 Jun 15;71(12):4226-35. doi: 10.1158/0008-5472.CAN-10-3810. Epub 2011 Apr 28.

43.

The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.

Hudlebusch HR, Santoni-Rugiu E, Simon R, Ralfkiær E, Rossing HH, Johansen JV, Jørgensen M, Sauter G, Helin K.

Clin Cancer Res. 2011 May 1;17(9):2919-33. doi: 10.1158/1078-0432.CCR-10-1302. Epub 2011 Mar 8.

44.

The level of claudin-7 is reduced as an early event in colorectal carcinogenesis.

Bornholdt J, Friis S, Godiksen S, Poulsen SS, Santoni-Rugiu E, Bisgaard HC, Lothe IM, Ikdahl T, Tveit KM, Johnson E, Kure EH, Vogel LK.

BMC Cancer. 2011 Feb 10;11:65. doi: 10.1186/1471-2407-11-65.

45.

Lipocalin 2 is protective against E. coli pneumonia.

Wu H, Santoni-Rugiu E, Ralfkiaer E, Porse BT, Moser C, Høiby N, Borregaard N, Cowland JB.

Respir Res. 2010 Jul 15;11:96. doi: 10.1186/1465-9921-11-96.

46.

Safety pharmacology, toxicology and pharmacokinetic assessment of human Gc globulin (vitamin D binding protein).

Pihl TH, Jørgensen CS, Santoni-Rugiu E, Leifsson PS, Hansen EW, Laursen I, Houen G.

Basic Clin Pharmacol Toxicol. 2010 Nov;107(5):853-60. doi: 10.1111/j.1742-7843.2010.00587.x.

47.

Ossifying thymoma associated with refractory myasthenia gravis.

Santoni-Rugiu E, Ravn J, Sehested M, Hansen K, Andersen CB.

APMIS. 2010 Apr;118(4):334-6. doi: 10.1111/j.1600-0463.2010.02595.x. No abstract available.

PMID:
20402680
48.

ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.

Vilmar A, Santoni-Rugiu E, Sørensen JB.

Eur J Cancer. 2010 Jun;46(9):1554-62. doi: 10.1016/j.ejca.2010.02.045. Epub 2010 Apr 13.

PMID:
20395129
49.

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.

Vilmar AC, Santoni-Rugiu E, Sørensen JB.

Ann Oncol. 2010 Sep;21(9):1817-24. doi: 10.1093/annonc/mdq053. Epub 2010 Mar 23.

PMID:
20332140
50.

Remarkable heterogeneity displayed by oval cells in rat and mouse models of stem cell-mediated liver regeneration.

Jelnes P, Santoni-Rugiu E, Rasmussen M, Friis SL, Nielsen JH, Tygstrup N, Bisgaard HC.

Hepatology. 2007 Jun;45(6):1462-70.

PMID:
17538966

Supplemental Content

Loading ...
Support Center